Altre lingue Axsome Therapeutics, Inc.

Azioni

AXSM

US05464T1043

Tempo reale stimato Cboe BZX Altri mercati azionari 17:30:30 03/07/2024			Variaz. 5gg	Var. 1 gen.
79,66 ^USD	+0,93%		+3,47%	+0,26%

05/06	AXSOME THERAPEUTICS, INC. : RBC Capital Markets rimane Buy	ZM
05/06	Axsome Therapeutics dichiara di aver risolto il contenzioso sul brevetto Sunosi con Unichem Laboratories	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Axsome therapeutics settles sunosi patent litigation with unichem laboratories	06/06
Axsome Therapeutics Says It Settled Sunosi Patent Litigation With Unichem Laboratories	05/06
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories	05/06
Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month	04/06
Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month	04/06
Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month	03/06
Axsome Therapeutics to Participate in Upcoming Investor Conferences	30/05
Axsome Therapeutics to Participate in Upcoming Investor Conferences	30/05
Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024	29/05
Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) Meeting	28/05
Axsome Therapeutics to Present at Upcoming Investor Conferences	08/05
Axsome Therapeutics to Present at Upcoming Investor Conferences	08/05
Axsome Therapeutics Q1 Loss Widens, Revenue Declines -- Shares Advance Pre-Bell	06/05
Axsome: Q1 Earnings Snapshot	06/05
Earnings Flash (AXSM) AXSOME THERAPEUTICS Posts Q1 Revenue $75M, vs. Street Est of $72.9M	06/05
Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update	06/05
Axsome Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	06/05
North American Morning Briefing : Stock Futures Rise as Hopes of Rate Cut Return	06/05
Axsome Therapeutics Recognizes May as Mental Health Awareness Month	01/05
North American Morning Briefing : More Earnings -2-	30/04

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Axsome Therapeutics, Inc.

Azioni

AXSM

US05464T1043

Altre lingue

Filtri